Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Thorac Dis
2016 Oct 01;810:2682-2688. doi: 10.21037/jtd.2016.09.64.
Show Gene links
Show Anatomy links
The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer.
Jia X
,
Qian R
,
Zhang B
,
Zhao S
.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide; unfortunately, its prognosis is still very poor. Therefore, developing the target molecular is very important for lung cancer diagnosis and treatment, especially in the early stage. With this in view, spalt-like transcription factor 4 (SALL4) is considered a potential biomarker for diagnosis and prognosis in cancers, including lung cancer.
METHODS: In order to better investigate the association between the expression of SALL4 and driver genes mutation, 450 histopathologically diagnosed patients with lung cancer and 11 non-cancer patients were enrolled to test the expression of SALL4 and the status of driver genes mutation. This investigation included epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral oncogene homolog (KRAS), and a fusion gene of the echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK).
RESULTS: The results of the study showed that females harbored more EGFR mutation in adenocarcinoma (ADC). The mutation rate of KRAS and EML4-ALK was about 5%, and the double mutations of EGFR/EML4-ALK were higher than EGFR/KRAS. In the expression analysis, the expression of SALL4 was much higher in cancer tissues than normally expected, especially in tissues that carried EGFR mutation (P<0.05), however, there were no significant differences between different mutation types. Likewise, there were no significant differences between expression of SALL4 and KRAS and EML4-ALK mutations.
CONCLUSIONS: SALL4 is up regulated in lung cancer specimens and harbors EGFR mutation; this finding indicates that SALL4 expression may be relevant with EGFR, which could provide a new insight to lung cancer therapy. The mechanism needs further investigation and analysis.
Al-Baradie,
Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family.
2002, Pubmed
Al-Baradie,
Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family.
2002,
Pubmed
Allemani,
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
2015,
Pubmed
Antoniu,
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
2011,
Pubmed
,
Echinobase
Ardalan Khales,
SALL4 as a new biomarker for early colorectal cancers.
2015,
Pubmed
Dearden,
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).
2013,
Pubmed
Fujimoto,
SALL4 immunohistochemistry in non-small-cell lung carcinomas.
2014,
Pubmed
Goldstraw,
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
2007,
Pubmed
Jiang,
A core Klf circuitry regulates self-renewal of embryonic stem cells.
2008,
Pubmed
Kobayashi,
Overexpression of SALL4 in lung cancer and its importance in cell proliferation.
2011,
Pubmed
Kohlhase,
Isolation, characterization, and organ-specific expression of two novel human zinc finger genes related to the Drosophila gene spalt.
1996,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications.
2012,
Pubmed
Liu,
Up-regulation of SALL4 associated with poor prognosis in gastric cancer.
2014,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Momenzadeh,
ZNF797 plays an oncogenic role in gastric cancer.
2014,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Pao,
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
2004,
Pubmed
Rodriguez,
Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC).
2014,
Pubmed
Tang,
Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).
2014,
Pubmed
Wang,
A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
2014,
Pubmed
Wu,
Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells.
2006,
Pubmed
Xiong,
Stemness factor Sall4 is required for DNA damage response in embryonic stem cells.
2015,
Pubmed
Yanagihara,
Significance of SALL4 as a drug‑resistant factor in lung cancer.
2015,
Pubmed
Zhang,
Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1.
2006,
Pubmed
Zhang,
The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome.
2015,
Pubmed
Zhang,
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
2015,
Pubmed
